search
Back to results

Short Course Primaquine for the Radical Cure of P. Vivax Malaria - Indonesia (SCOPE)

Primary Purpose

Vivax Malaria, G6PD Deficiency

Status
Not yet recruiting
Phase
Not Applicable
Locations
Indonesia
Study Type
Interventional
Intervention
Revised case management package
Sponsored by
Menzies School of Health Research
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Vivax Malaria focused on measuring Primaquine

Eligibility Criteria

6 Months - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Patients with vivax malaria Exclusion Criteria: Patients who are pregnant Patients who are breastfeeding Patients with a Hb <8g/dL Patients with a previous adverse reaction to primaquine Patient with severe malaria

Sites / Locations

  • Puskesmas Hanura
  • Puskesmas Tanjung Leidong
  • Puskesmas Bhintuka
  • Puskesmas Pasar Sentral
  • Puskesmas Timika
  • Puskesmas Wania

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Revised case management package

Arm Description

Outcomes

Primary Outcome Measures

Proportion of patients experiencing at least one Serious Adverse Event (SAE) during treatment
SAEs are collected during clinical review using a study-specific questionnaire
Proportion of patients experiencing at least one Adverse Event of Special Interest(AESI) during treatment
AESIs (haemolysis, methaemoglobinaemia and gastrointestinal discomfort) are collected during clinical review using a study-specific questionnaire
Proportion of patients with P. vivax malaria who correctly receive all components of the revised case management package
Measured by completion of G6PD testing and the correct prescription of primaquine based on G6PD activity, completion of patients counselling and community based follow up on Day 3

Secondary Outcome Measures

The proportion of patients with any AESI during treatment
AESIs are collected during clinical review using a study-specific questionnaire
The proportion of patients with a gastrointestinal (GI) AESI during treatment
AESIs are collected during clinical review using a study-specific questionnaire
The proportion of patients with an AESI related to haemolysis during treatment
AESIs are collected during clinical review using a study-specific questionnaire
The proportion of patients an AESI related to methaemoglobinaemia
AESIs are collected during clinical review using a study-specific questionnaire
Proportion of patients permanently stopping PQ before end of treatment
Discontinuation of PQ will be assessed using a study-specific questionnaire
The proportion of patients receiving correct treatment based on G6PD activity
This will be assessed by linking patients G6PD activity results measured during study enrolment with primaquine dose prescribed on the same day
Proportion of patients who were reviewed on Day 3 and Day 7
This will be assessed by linking patients enrolment data with Day 3 and Day 7clinical review data
Perception of and experience with new radical cure tools among health care providers and community members
This will be assessed using stakeholder interviews
Proportion of health care practitioners who comply with the revised radical cure treatment algorithm
The outcome will be assessed from patients' enrolment data
Proportion of patients receiving a SD Biosensor G6PD test
The outcome will be assessed from patients' enrolment data
Proportion of eligible P. vivax malaria patients receiving the correct dose of primaquine based on the result of the G6PD test
The outcome will be assessed from patients' enrolment data
Proportion of P. vivax malaria patients who are ineligible for daily primaquine and are incorrectly given primaquine (including infants, pregnant females and G6PD deficient patients
The outcome will be assessed from patients' enrolment data
Proportion of P. vivax malaria patients that are reviewed on Day 3
This will be assessed by linking patients' enrolment data with clinical review data
Proportion of P. vivax malaria patients that adhere to their prescribed primaquine regimen
This will be assessed by linking patients' enrolment data with clinical review data
Factors influencing acceptability and feasibility of the new radical cure tools among health care providers are identified
This will be assessed using stakeholder interviews, observations and focus groups
Barriers and enablers of uptake and implementation at the sub-national levels are identified
This will be assessed using stakeholder interviews and focus groups
Factors influencing compliance with G6PD testing and perceptions of new drug regimens and serious adverse events among health care providers are identified
This will be assessed using stakeholder interviews and focus groups
Required knowledge, skills, and training to administer the revised case management and patient-counselling identified
This will be assessed using stakeholder interviews and focus groups
Factors influencing the barriers and facilitators to patient adherence to primaquine after the rollout of the revised case management identified
This will be assessed using stakeholder interviews and focus groups
Factors influencing the acceptability and feasibility of community-based clinical review at Day 3 of primaquine treatment identified
This will be assessed using stakeholder interviews and focus groups
Perceptions of the new radical cure tools and serious adverse events at the community level identified
This will be assessed using stakeholder interviews and focus groups
Local acceptability of the revised case management algorithms among patients, their families, and healthcare workers established
This will be assessed using stakeholder interviews and focus groups
The monthly incidence of confirmed symptomatic P. vivax malaria episodes (mono-infection or mixed) before implementation versus after implementation
This will be assessed by comparing facility surveillance data before implementation with facility surveillance data after implementation
The prevalence of P. vivax parasitaemia in patients presenting with fever before implementation versus after implementation
This will be assessed by comparing cross-sectional data on n=200 patients (per facility) collected before implementation to the prevalence collected in n=200patients (per facility) after implementation
Cumulative risk of representation to the same clinic with symptomatic P. vivax malaria within 6 months
This will be assessed by linking patients' enrolment data
Costs of implementing policy from a healthcare provider perspective, including health systems strengthening processes
This will be assessed from health system data collected throughout the study
Household costs per P. vivax episode
This will be assessed from a household cost survey on a subset of patients
Overall cost-effectiveness of changing policy if revised case management is effective
This will be assessed from health system data collected throughout the study
Cost per episode of P. vivax malaria from the healthcare provider and societal perspectives
This will be assessed from health system data collected throughout the study
Cost per component of the revised case management package
This will be assessed from health system data collected throughout the study
If revised case management package is effective (significantly reduces the incidence of malaria), then the cost-effectiveness of implementing the revised case management as compared with usual care
This will be assessed from health system data collected throughout the study
Proportion of CHWs who correctly act on early signs of haemolytic anaemia and GI events (i.e. refer patients for further medical review, instruct patient to discontinue treatment)
This will be assessed from clinical review data and study-specific questionnaire
Number of patients with an SAE who are identified by community or clinic staff follow-up and referred to hospital for further management
This will be assessed by linking clinical review data, study specific questionnaire and SAE form
The proportion of patients eligible to receive PQ who had a SAE during treatment
This will be assessed by linking enrolment data, clinical review, study specific questionnaire and SAE form
Prevalence of severe anaemia in patients presenting with fever before and after implementation
This will be assessed by comparing the facility surveillance data before implementation with facility surveillance data after implementation

Full Information

First Posted
May 18, 2023
Last Updated
June 19, 2023
Sponsor
Menzies School of Health Research
Collaborators
Gadjah Mada University, Universitas Sumatera Utara, Indonesia University, Yayasan Pengembangan Kesehatan dan Masyarakat, Indonesian National Malaria Control Program, Ministry of Health, National Research and Innovation Agency of Indonesia, Burnet Institute, University of Melbourne, Medicines for Malaria Venture, PATH, UNITAID, Institute of Tropical Medicine, Belgium
search

1. Study Identification

Unique Protocol Identification Number
NCT05879224
Brief Title
Short Course Primaquine for the Radical Cure of P. Vivax Malaria - Indonesia
Acronym
SCOPE
Official Title
Feasibility of High Daily Dose Short Course Primaquine After G6PD Testing for the Radical Cure of Plasmodium Vivax Malaria
Study Type
Interventional

2. Study Status

Record Verification Date
June 2023
Overall Recruitment Status
Not yet recruiting
Study Start Date
July 1, 2023 (Anticipated)
Primary Completion Date
May 31, 2025 (Anticipated)
Study Completion Date
July 31, 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Menzies School of Health Research
Collaborators
Gadjah Mada University, Universitas Sumatera Utara, Indonesia University, Yayasan Pengembangan Kesehatan dan Masyarakat, Indonesian National Malaria Control Program, Ministry of Health, National Research and Innovation Agency of Indonesia, Burnet Institute, University of Melbourne, Medicines for Malaria Venture, PATH, UNITAID, Institute of Tropical Medicine, Belgium

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The proportion of malaria that is the Plasmodium vivax species is increasing in Indonesia. Reducing vivax malaria will require innovative solutions to cure both the blood and liver stages of the disease. This study will evaluate of the feasibility of implementing point-of-care glucose-6-phosphate dehydrogenase deficiency (G6PD) testing. This will be followed by high dose, short course primaquine treatment regimens for patients with vivax malaria, and combined with patient education, surveillance, and pharmacovigilance. We plan to implement the study at 6 health facilities across Indonesia using a staged before-and-after study, with a mixed method evaluation.
Detailed Description
Significant gains have been made in reducing the overall burden of malaria worldwide, however these have been far greater for Plasmodium falciparum than P. vivax. P. vivax remains a major obstacle to malaria control and elimination efforts, largely due to its ability to form dormant liver stages (hypnozoites) that allow it to escape detection and treatment. Importantly, they are susceptible only to 8 aminoquinolines such as primaquine however, primaquine is associated with risk of haemolysis in individuals with a genetic condition, called glucose-6-phosphate dehydrogenase (G6PD) deficiency. Additionally, the recommended 14-day prolonged treatment regimen is associated with poor treatment adherence hence ineffective primaquine treatment. Innovative solutions to the radical cure of both the blood and liver stages of P. vivax are urgently required. The Indonesian Ministry of Health has requested a pragmatic study of the feasibility and cost-effectiveness of implementing point-of-care G6PD testing followed by high-dose, short-course primaquine treatment regimens for patients with vivax malaria. These interventions are to be combined with practicable enhancements to patient education, supervision, malariometric surveillance and pharmacovigilance. This will be a before-after longitudinal health facility-based study implemented at six sites in Indonesia; four in Papua, one in North Sumatra and one in Lampung. We will use a staged approach for the implementation of the revised case management strategy, including patient education and counselling,community-based clinical review, with mixed methods evaluation.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Vivax Malaria, G6PD Deficiency
Keywords
Primaquine

7. Study Design

Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Model Description
Combination Product: Revised case management package
Masking
None (Open Label)
Allocation
N/A
Enrollment
11250 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Revised case management package
Arm Type
Experimental
Intervention Type
Combination Product
Intervention Name(s)
Revised case management package
Intervention Description
Point-of-care quantitative G6PD testing using G6PDSTANDARD (SD Biosensor) prior to use of primaquine (Day 0) Prescription of short course primaquine (7 mg/kg total)(Day 0): PQ7 (1 mg/kg/day for 7 days) if G6PD activity greater than 70 percent PQ14 (0.5 mg/kg/day for 14 days) if G6PDactivity is 30-70 percent PQ8w (0.75 mg/kg/week for 8 weeks) if G6DPactivity less than 30 percent Participant counselling at the health facility (Day 0): Supervision of first dose of primaquine Education regarding the importance and risks of primaquine therapy and necessity to take primaquine with food Community based clinical review on Day 3 (and Day 7 for the first 300 participants) to detect and manage gastrointestinal or haemolytic adverse effects of treatment and encourage adherence to full treatment regime Improved malariometric surveillance and pharmacovigilance to support wider scale use of the revised case management
Primary Outcome Measure Information:
Title
Proportion of patients experiencing at least one Serious Adverse Event (SAE) during treatment
Description
SAEs are collected during clinical review using a study-specific questionnaire
Time Frame
During treatment (up to 8 weeks) ]
Title
Proportion of patients experiencing at least one Adverse Event of Special Interest(AESI) during treatment
Description
AESIs (haemolysis, methaemoglobinaemia and gastrointestinal discomfort) are collected during clinical review using a study-specific questionnaire
Time Frame
During treatment (up to 8 weeks)
Title
Proportion of patients with P. vivax malaria who correctly receive all components of the revised case management package
Description
Measured by completion of G6PD testing and the correct prescription of primaquine based on G6PD activity, completion of patients counselling and community based follow up on Day 3
Time Frame
3 days
Secondary Outcome Measure Information:
Title
The proportion of patients with any AESI during treatment
Description
AESIs are collected during clinical review using a study-specific questionnaire
Time Frame
During treatment (up to 8 weeks)
Title
The proportion of patients with a gastrointestinal (GI) AESI during treatment
Description
AESIs are collected during clinical review using a study-specific questionnaire
Time Frame
During treatment (up to 8 weeks)
Title
The proportion of patients with an AESI related to haemolysis during treatment
Description
AESIs are collected during clinical review using a study-specific questionnaire
Time Frame
During treatment (up to 8 weeks) ]
Title
The proportion of patients an AESI related to methaemoglobinaemia
Description
AESIs are collected during clinical review using a study-specific questionnaire
Time Frame
During treatment (up to 8 weeks)
Title
Proportion of patients permanently stopping PQ before end of treatment
Description
Discontinuation of PQ will be assessed using a study-specific questionnaire
Time Frame
During treatment (up to 8 weeks)
Title
The proportion of patients receiving correct treatment based on G6PD activity
Description
This will be assessed by linking patients G6PD activity results measured during study enrolment with primaquine dose prescribed on the same day
Time Frame
1 day
Title
Proportion of patients who were reviewed on Day 3 and Day 7
Description
This will be assessed by linking patients enrolment data with Day 3 and Day 7clinical review data
Time Frame
1 week
Title
Perception of and experience with new radical cure tools among health care providers and community members
Description
This will be assessed using stakeholder interviews
Time Frame
6 months
Title
Proportion of health care practitioners who comply with the revised radical cure treatment algorithm
Description
The outcome will be assessed from patients' enrolment data
Time Frame
1 day
Title
Proportion of patients receiving a SD Biosensor G6PD test
Description
The outcome will be assessed from patients' enrolment data
Time Frame
1 day
Title
Proportion of eligible P. vivax malaria patients receiving the correct dose of primaquine based on the result of the G6PD test
Description
The outcome will be assessed from patients' enrolment data
Time Frame
1 day
Title
Proportion of P. vivax malaria patients who are ineligible for daily primaquine and are incorrectly given primaquine (including infants, pregnant females and G6PD deficient patients
Description
The outcome will be assessed from patients' enrolment data
Time Frame
1 day
Title
Proportion of P. vivax malaria patients that are reviewed on Day 3
Description
This will be assessed by linking patients' enrolment data with clinical review data
Time Frame
3 days
Title
Proportion of P. vivax malaria patients that adhere to their prescribed primaquine regimen
Description
This will be assessed by linking patients' enrolment data with clinical review data
Time Frame
3 days
Title
Factors influencing acceptability and feasibility of the new radical cure tools among health care providers are identified
Description
This will be assessed using stakeholder interviews, observations and focus groups
Time Frame
3 days
Title
Barriers and enablers of uptake and implementation at the sub-national levels are identified
Description
This will be assessed using stakeholder interviews and focus groups
Time Frame
18 months
Title
Factors influencing compliance with G6PD testing and perceptions of new drug regimens and serious adverse events among health care providers are identified
Description
This will be assessed using stakeholder interviews and focus groups
Time Frame
18 months
Title
Required knowledge, skills, and training to administer the revised case management and patient-counselling identified
Description
This will be assessed using stakeholder interviews and focus groups
Time Frame
18 months
Title
Factors influencing the barriers and facilitators to patient adherence to primaquine after the rollout of the revised case management identified
Description
This will be assessed using stakeholder interviews and focus groups
Time Frame
18 months
Title
Factors influencing the acceptability and feasibility of community-based clinical review at Day 3 of primaquine treatment identified
Description
This will be assessed using stakeholder interviews and focus groups
Time Frame
18 months
Title
Perceptions of the new radical cure tools and serious adverse events at the community level identified
Description
This will be assessed using stakeholder interviews and focus groups
Time Frame
18 months
Title
Local acceptability of the revised case management algorithms among patients, their families, and healthcare workers established
Description
This will be assessed using stakeholder interviews and focus groups
Time Frame
Day 3
Title
The monthly incidence of confirmed symptomatic P. vivax malaria episodes (mono-infection or mixed) before implementation versus after implementation
Description
This will be assessed by comparing facility surveillance data before implementation with facility surveillance data after implementation
Time Frame
18 months
Title
The prevalence of P. vivax parasitaemia in patients presenting with fever before implementation versus after implementation
Description
This will be assessed by comparing cross-sectional data on n=200 patients (per facility) collected before implementation to the prevalence collected in n=200patients (per facility) after implementation
Time Frame
18 months
Title
Cumulative risk of representation to the same clinic with symptomatic P. vivax malaria within 6 months
Description
This will be assessed by linking patients' enrolment data
Time Frame
18 months
Title
Costs of implementing policy from a healthcare provider perspective, including health systems strengthening processes
Description
This will be assessed from health system data collected throughout the study
Time Frame
18 months
Title
Household costs per P. vivax episode
Description
This will be assessed from a household cost survey on a subset of patients
Time Frame
3 days
Title
Overall cost-effectiveness of changing policy if revised case management is effective
Description
This will be assessed from health system data collected throughout the study
Time Frame
18 months
Title
Cost per episode of P. vivax malaria from the healthcare provider and societal perspectives
Description
This will be assessed from health system data collected throughout the study
Time Frame
18 months
Title
Cost per component of the revised case management package
Description
This will be assessed from health system data collected throughout the study
Time Frame
18 months
Title
If revised case management package is effective (significantly reduces the incidence of malaria), then the cost-effectiveness of implementing the revised case management as compared with usual care
Description
This will be assessed from health system data collected throughout the study
Time Frame
18 months
Title
Proportion of CHWs who correctly act on early signs of haemolytic anaemia and GI events (i.e. refer patients for further medical review, instruct patient to discontinue treatment)
Description
This will be assessed from clinical review data and study-specific questionnaire
Time Frame
3 days
Title
Number of patients with an SAE who are identified by community or clinic staff follow-up and referred to hospital for further management
Description
This will be assessed by linking clinical review data, study specific questionnaire and SAE form
Time Frame
During treatment (up to 8 weeks)
Title
The proportion of patients eligible to receive PQ who had a SAE during treatment
Description
This will be assessed by linking enrolment data, clinical review, study specific questionnaire and SAE form
Time Frame
During treatment (up to 8 weeks)
Title
Prevalence of severe anaemia in patients presenting with fever before and after implementation
Description
This will be assessed by comparing the facility surveillance data before implementation with facility surveillance data after implementation
Time Frame
18 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
6 Months
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients with vivax malaria Exclusion Criteria: Patients who are pregnant Patients who are breastfeeding Patients with a Hb <8g/dL Patients with a previous adverse reaction to primaquine Patient with severe malaria
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Vanessa Sakalidis, PhD
Phone
+614 08 8946 8600
Email
vanessa.sakalidis@menzies.edu.au
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ric Price, MD
Organizational Affiliation
Menzies School of Health Research
Official's Role
Principal Investigator
Facility Information:
Facility Name
Puskesmas Hanura
City
Hanura
State/Province
Lampung
Country
Indonesia
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Inge Sutanto, MD
Email
sutanto.inge@yahoo.com
First Name & Middle Initial & Last Name & Degree
Inge Sutanto, MD
Facility Name
Puskesmas Tanjung Leidong
City
Labuhanbatu
State/Province
North Sumatra
Country
Indonesia
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ayodhia Pasaribu, MD
Email
ayodhia@usu.ac.id
First Name & Middle Initial & Last Name & Degree
Ayodhia Pasaribu, MD
Facility Name
Puskesmas Bhintuka
City
Mimika
State/Province
Papua
Country
Indonesia
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jeanne R Poespoprodjo, MD
Email
didot2266@yahoo.com
First Name & Middle Initial & Last Name & Degree
Jeanne R Poespoprodjo, MD
Facility Name
Puskesmas Pasar Sentral
City
Mimika
State/Province
Papua
Country
Indonesia
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jeanne R Poespoprodjo, MD
Email
didot2266@yahoo.com
First Name & Middle Initial & Last Name & Degree
Jeanne R Poespoprodjo, MD
Facility Name
Puskesmas Timika
City
Mimika
State/Province
Papua
Country
Indonesia
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jeanne R Poespoprodjo, MD
Email
didot2266@yahoo.com
First Name & Middle Initial & Last Name & Degree
Jeanne R Poespoprodjo, MD
Facility Name
Puskesmas Wania
City
Mimika
State/Province
Papua
Country
Indonesia
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jeanne R Poespoprodjo, MD
Email
didot2266@yahoo.com
First Name & Middle Initial & Last Name & Degree
Jeanne R Poespoprodjo, MD

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
Study Protocol and Statistical Analysis Plan will be made available to others. The results will be published in peer-reviewed open access journals and disseminated to stakeholders. De-identified quantitative data for the purposes of confirming risk of adverse events will be available to researchers who provide a methodological sound proposal that is in line with the aims of the approved protocol.
IPD Sharing Access Criteria
Access is subject to approval by the SCOPE Data Access Committee to ensure that the use of data protects the interests of the participants and researchers according to the terms of ethics approval and principles of equitable data sharing. Requests can be submitted to the Requests can be submitted to Professor Ric Price, Menzies School of Health Research, Email:ric.price@menzies.edu.au and Dr Jeanne Rini Poespoprodjo, Universitas Gadjah Mada, Email:didot2266@yahoo.com

Learn more about this trial

Short Course Primaquine for the Radical Cure of P. Vivax Malaria - Indonesia

We'll reach out to this number within 24 hrs